Dr. Charles Mok explains that semaglutide lowers cardiovascular event risk in people with diabetes or at high risk, but the benefit is unclear for those without diabetes. Weight-loss doses are about 10 times lower than doses used in cardiovascular studies, and side effects are a real concern.
Chapters
Another thing that I'm thinking about with this, because when semaglutide first came out, we didn't really know as much about it as we do now. Semaglutide appears to lower the risk of cardiovascular events, particularly in people at risk and with diabetes. Now it's unknown will this lower the risk of cardiovascular disease in people that do not have cardiovascular risk or do not have diabetes, but logic would suggest that it can. It also reduces some autoimmune syndromes and it reduces some other bad habitual activities. So there's some benefit to using this to stimulating GLP1 long term. The downside is it's got a lot of side effects when it's taken at that higher dose, at 10 times higher than the weight loss dose.